Actualités et vidéos - IONIS PHARMACEUTICALS INC.

Ionis presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema PR Newswire CARLSBAD, Calif., May 31, 2024 Donidalorsen delivered significant and sustained reductions in HAE attacks, with high levels of disease control and improvement in quality of life measures with monthly or every two-month dosing; continued attack rate reduction over time In first-of-its-kind prospective analysis, patients switching from...

Ionis to hold donidalorsen Phase 3 data webcast PR Newswire CARLSBAD, Calif., May 28, 2024 Webcast scheduled for Friday, May 31 at 8:00 a.m. Eastern Time CARLSBAD, Calif. , May 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Friday, May 31 th at 8:00 a.m. Eastern Time to discuss the donidalorsen Phase 3 OASIS-HAE and OASISplus (Open-Label Extension and Switch cohorts) study results that will be presented in three...

New data from the Phase 3 NEURO-TTRansform study evaluating WAINUA™ (eplontersen) to be presented at the 2024 International Symposium on Amyloidosis (ISA) PR Newswire CARLSBAD, Calif., May 23, 2024 – Results across NEURO-TTRansform subgroups show consistent benefit in neuropathy impairment and improved quality of life, regardless of patient segmentation – CARLSBAD, Calif. , May 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new...

Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis PR Newswire CARLSBAD, Calif. and CAMBRIDGE, Mass., May 16, 2024 Development of BIIB105, an investigational antisense oligonucleotide for amyotrophic lateral sclerosis (ALS), will be discontinued based on data from the Phase 1/2 ALSpire study Biogen and Ionis continue their long-standing commitment to developing therapies for ALS given the devastating impact of this progressive,...

Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome PR Newswire CARLSBAD, Calif., May 16, 2024 ION582 demonstrated consistent improvements across multiple functional domains in Angelman syndrome patients ION582 was safe and well tolerated at all dose levels Ionis plans to move ION582 into pivotal trial Detailed ION582 data to be presented at upcoming medical meeting CARLSBAD, Calif. , May 16, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq:...

Ionis to host 2024 virtual Annual Meeting of Stockholders PR Newswire CARLSBAD, Calif., May 15, 2024 CARLSBAD, Calif. , May 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a general corporate update on Thursday, June 6, 2024 . The agenda for the event is as follows: 5:00 p.m. – 5:15 p.m. ET ( 2:00 p.m. – 2:15 p.m. PT ) – Virtual Annual Meeting of Stockholders All...

Ionis reports first quarter 2024 financial results PR Newswire CARLSBAD, Calif., May 7, 2024 WAINUA TM launch on track; EU and Canada approval decisions expected this year Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission Positive Phase 3 donidalorsen data for HAE; preparing regulatory submissions On track to achieve 2024 financial guidance CARLSBAD, Calif. , May 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company"), today reported financial...

Ionis Publishes 2023 Corporate Responsibility Report PR Newswire CARLSBAD, Calif., April 25, 2024 Established new corporate responsibility strategic pillars and actionable goals Received approval for two Ionis-discovered medicines in 2023, and continued to advance a broad pipeline poised to bring a steady cadence of important new medicines to people with serious diseases CARLSBAD, Calif. , April 25, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today published its 2023...

Ionis to hold first quarter 2024 financial results webcast PR Newswire CARLSBAD, Calif., April 23, 2024 Webcast scheduled for Tuesday, May 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , April 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Tuesday, May 7 th at 11:30 a.m. Eastern Time to discuss its first quarter 2024 financial results. The webcast may be accessed at...

Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome PR Newswire CARLSBAD, Calif., April 7, 2024 – Olezarsen met the primary endpoint with statistically significant reduction of fasting triglycerides and showed substantial, clinically meaningful reduction in acute pancreatitis events – – Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved...

Ionis to present at upcoming investor conferences PR Newswire CARLSBAD, Calif., April 1, 2024 CARLSBAD, Calif. , April 1, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: 23 rd Annual Needham Virtual Healthcare Conference on Monday, April 8, 2024 2024 RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024 BofA Securities Health Care Conference 2024 on...

Ionis to hold olezarsen Phase 3 data webcast PR Newswire CARLSBAD, Calif., March 28, 2024 Webcast scheduled for Monday, April 8 at 10:00 a.m. Eastern Time CARLSBAD, Calif. , March 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Monday, April 8 th at 10:00 a.m. Eastern Time to discuss the olezarsen Phase 3 Balance study results in patients with familial chylomicronemia syndrome (FCS) presented at the 2024 American College of...

Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting PR Newswire CARLSBAD, Calif., March 25, 2024 – First presentation of pivotal results showing significant reduction in triglycerides and substantial reduction in acute pancreatitis events in patients with rare, life-threatening disease, for which there are no approved treatment options in U.S. – CARLSBAD, Calif. , March 25, 2024 /PRNewswire/ -- Ionis...

Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH PR Newswire CARLSBAD, Calif., March 13, 2024 Significant improvement in steatohepatitis with > 2 point improvement in NAS score without worsening fibrosis, the primary endpoint of the study Achieved key secondary endpoint of MASH resolution without worsening of fibrosis More ION224 treated patients had an improvement of > 1 stage fibrosis...

Ionis announces new chief global product strategy officer to lead next phase of commercial growth PR Newswire CARLSBAD, Calif., Feb. 29, 2024 Kyle Jenne rejoins company to lead commercial strategy Onaiza Cadoret-Manier departing for new career opportunity With broad commercial capabilities in place, Ionis ready to execute on its first independent launches CARLSBAD, Calif. , Feb. 29, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Kyle Jenne has rejoined Ionis...

Ionis to present at upcoming investor conferences PR Newswire CARLSBAD, Calif., Feb. 28, 2024 CARLSBAD, Calif. , Feb. 28, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: TD Cowen 44 th Annual Health Care Conference on Tuesday, March 5, 2024 Stifel 2024 Virtual CNS Days on Wednesday, March 20, 2024 A live webcast of these presentations can be accessed on the Investors & Media...

Ionis reports fourth quarter and full year 2023 financial results PR Newswire CARLSBAD, Calif., Feb. 21, 2024 WAINUA™ approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthough Therapy designation by the FDA for FCS Ionis provides full year 2024 financial guidance CARLSBAD, Calif. , Feb. 21, 2024 /PRNewswire/ -- Ionis...

Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome PR Newswire CARLSBAD, Calif., Feb. 15, 2024 CARLSBAD, Calif. , Feb. 15, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to the investigational medicine olezarsen for the treatment of familial chylomicronemia syndrome (FCS), a rare, genetic disease characterized by extremely elevated...

Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy PR Newswire CARLSBAD, Calif., Feb. 8, 2024 CARLSBAD, Calif. , Feb. 8, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis and AstraZeneca's eplontersen, an investigational therapy for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) in...

Ionis to hold fourth quarter and full year 2023 financial results webcast PR Newswire CARLSBAD, Calif., Feb. 7, 2024 Webcast scheduled for Wednesday, February 21 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 7, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 21 st at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2023 financial results. The live webcast may be accessed at...